FINWIRES · TerminalLIVE
FINWIRES

傑富瑞表示,Scentre集團已為高通膨環境做好準備

-- 傑富瑞(Jefferies)週三在一份報告中指出,Scentre Group(ASX:SCG)在高通膨環境下佔據有利地位,這得益於其租賃結構,其中約80%的專業租賃與消費者物價指數掛鉤。 該公司近期公佈,截至3月31日的三個月內,其投資組合中所有業務合作夥伴的總銷售額年增5%,達到70億澳元,主要得益於專業銷售額5.3%的成長。 截至3月31日,其投資組合的入住率為99.8%,較去年同期成長20個基點。 該公司重申了本財年營運資金目標,即每股至少0.2373澳元。這一目標基於其第一季的營運業績,相當於至少4%的成長。傑富瑞表示,考慮到今年諸多獲利挑戰,這項業績「值得稱讚」。 這家金融服務公司表示,不利因素包括:2025財年部分出售Chermside和雪梨購物中心的股份導致股權稀釋;Westfield Bondi耗資2.4億澳元的重建項目;以及自今年起,由於Bondi項目為全資所有,預計項目收入將有所下降。 傑富瑞將Scentre Group的評級從“持有”上調至“買入”,並維持4澳元的目標價。 Scentre Group股價週四午盤上漲1%。

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703